Recently, CDE website news, Yangtze River Pharmaceutical Group wholly-owned subsidiary Shanghai Haiyan Pharmaceutical Technology Co.
, Ltd.
Class 1 new drug YZJ-4729 tartrate injection was approved clinically
.
According to public information, the newly approved clinical YZJ-4729 tartrate injection is a G-protein biased μ opioid receptor (MOR) agonist, which can selectively activate the G protein pathway to exert a potent analgesic effect, while avoiding activating the β-arresti-2 pathway to alleviate opioid adverse reactions
such as respiratory depression and gastrointestinal dysfunction.
Currently, only one biased μ-opioid agonist has been approved globally, and Osperidine fumarate injection is used to treat acute severe pain
in adults who require intravenous opioids and are poorly controlled by alternative therapies.
In vitro tests have shown that YZJ-4729 has a higher bias than the American listed oselidine, and the pharmacokinetic properties and blood-brain barrier permeability are better, and the selectivity of other opioid receptors is also better; In vivo, dose-dependent potent analgesic effects
are exhibited in different animal pain models.
The industry expects that if the drug can be successfully listed, it will help Yangtze River Pharmaceutical to strengthen its position
in the nervous system drug market.
Neurological diseases occur in the central nervous system, peripheral nervous system, and autonomic nervous system, with sensory, motor, conscious, and autonomic nerve dysfunction as the main
manifestations.
Current drugs for the nervous system can be subdivided into subcategories
such as anesthetics, analgesics, antiepileptic drugs, anti-tremor paralysis, and neuroleptics.
It is understood that the nervous system drug market is one of the fist areas of Yangtze River Pharmaceutical Group, since 2018, Yangtze River Pharmaceutical has dominated the nervous system drug market
in China's public medical institutions.
It has advantages in many segments, and its research and development strength is also at the forefront
of the industry.
For example, Dizoxin injection is a large variety with an annual sales of 7.
3 billion yuan (2021 hospital sales data), and the vast majority of the current share is controlled
by Yangtze River Pharmaceutical.
Its main role is analgesia, used for postoperative analgesia and pain caused by internal organs and cancer, and is listed as a class II psychotropic drug control
.
According to the data, among the 1 new drugs that Yangzijiang Pharmaceutical has been approved for clinical practice, neurological drugs account for 4
.
Among them, the first class of new drugs that have been approved for clinical treatment in the field of analgesia are YZJ-1495 hydrochloride capsules and YR-1702 injections, and the two new drugs have now entered the phase I clinical clinic and are progressing smoothly
.
In fact, in recent years, Yangtze River Pharmaceutical and its subsidiaries are still increasing the research and development of nervous system drugs, in addition to the advantages of pain relief, mental stability, local anesthesia, but also expanded to other subcategories
.
For example, in 2021, it won the nanobuphine hydrochloride injection, breaking the situation
that Renfu Pharmaceutical had previously monopolized the market.
However, it is worth noting that the considerable market is making pharmaceutical companies continue to increase the research and development and declaration
of drugs for the nervous system.
As of September 10, 6 new drugs have been approved for listing this year, and at the same time, 11 new drugs from Hengrui Pharmaceutical, Yichang Renfu, Haisco and other enterprises have also submitted listing applications and are currently under
review and approval.
As a result, the industry expects that the market competition faced by Yangtze River Pharmaceutical will continue to intensify
.
In the future, how to work new preparations and form differentiated competition may become the main problem
in its development in this field.
